KHN-922

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameKHN-922

Drug Alias NameKHN-922

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionDNA topoisomerase I inhibitorsRNA polymerase II inhibitorsAnti-Receptor tyrosine-protein kinase erbB-3

TargetsDNA topoisomerase IRNA polymerase IIReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesChengdu Kanghong Pharmaceutical Group Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Kanghong Biotechnologies Co Ltd

Inactive CompaniesChengdu Kanghong Pharmaceutical Group Co Ltd

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A